FDA 510(k)
FDA class 2
Substantially Equivalent
🇺🇸 United States
Access EPO
K Number: K240182
·
Decision Apr 22, 2024
Classifications
1
FEI Numbers
9
Registration Numbers
9
Same Product Code
19
Applicant Total
270
Review Days
90
Research this 510(k) in seconds
The Research Assistant summarizes clearance history, predicates and product-code trends — and cites every record.
Free to try · every answer cites its records
Basic Information
- Device Name
- Access EPO
- K Number
- K240182
- Device Class
- FDA class 2
- Clearance Type
- Traditional
- Regulation Number
- 864.7250
- Medical Specialty
- Hematology
- Decision
- Substantially Equivalent
- Statement or Summary
- Summary
- Applicant
- Beckman Coulter, Inc.
- Date Received
- January 23, 2024
- Decision Date
- April 22, 2024
- Product Code
- GGT
- Advisory Committee
- Hematology
- Review Advisory Committee
- HE
- Third Party
- N
Classifications
This FDA 510(k) entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| GGT | Assay, Erythropoietin | FDA class 2 | Hematology |
Similar 510(k) Clearances
Other 510(k) clearances with the same product code (GGT), ordered by most recent decision date.
ADVIA Centaur Erythropoietin (EPO) assay
FDA 510(k)
FDA Class 2
·Hematology
ACCESS EPO ASSAY
FDA 510(k)
FDA Class 2
·Hematology
SANGUI BIOTECH, INC. EPO (ERYTHROPOIETIN) ELISA KIT
FDA 510(k)
FDA Class 2
·Hematology
IMMULITE EPO, MODEL #'S LKEPZ & LKEP1
FDA 510(k)
FDA Class 2
·Hematology
ADVANTAGE CHEMILUMINESCENCE ERYTHROPOIETIN IMMUNOASSAY
FDA 510(k)
FDA Class 2
·Hematology
ERYTHROPOIETIN IMMUNOASSAY KIT
FDA 510(k)
FDA Class 2
·Hematology
Other Clearances by Beckman Coulter, Inc.
| K Number | Device Name | ||
|---|---|---|---|
| K252169 | Access BNP II | Mar 24, 2026 | Substantially Equivalent |
| K254059 | Access anti-HBc IgM | Mar 13, 2026 | Substantially Equivalent |
| K253687 | Access anti-HBc Total | Feb 19, 2026 | Substantially Equivalent |
| K251995 | Access anti-HAV IgM | Jan 27, 2026 | Substantially Equivalent |
| K250588 | Access Rubella IgG | Nov 17, 2025 | Substantially Equivalent |
| K252580 | iQ200 Series | Sep 10, 2025 | Substantially Equivalent |
| K243846 | Access anti-HAV | Sep 9, 2025 | Substantially Equivalent |
| K243804 | MicroScan Dried Gram-Negative MIC/Combo Panels with Cefepime (CPE) (0.12-64 µg/mL) (MicroScan) | Aug 20, 2025 | Substantially Equivalent |
| K250036 | MicroScan Dried Gram-Positive MIC/Combo Panels with Daptomycin (DAP) (0.06-32 µg/mL) | Aug 15, 2025 | Substantially Equivalent |
| K243483 | Access hsTnI | Aug 1, 2025 | Substantially Equivalent |